Published On: Sun, Jan 20th, 2019

MedCu received FDA approval for a copper-based dressing product

MedCu has developed a technology for the integration of oxidized copper with bandages for antibacterial treatment and prevention of chronic wound infections.

Israeli company, MedCu has received approval from the Food and Drug Administration (FDA) to market a copper-based dressing product ideal for acute, diabetic and chronic wounds.

Following the approval, MedCu plans to raise $5 million at an estimated value of  20-25 million. MedCu Technologies is currently also seeking distributors in Europe and other territories.

Founded in 2016 by Danny Lustiger and Dr. Gadi Borkov, MedCu’s products are impregnated with materials that make up the bandages to create an antibacterial environment and prevent infections and healing difficulties. Copper is a natural mineral essential to the human body. It has been shown to be effective against a wide range of infections, including those that have developed resistance

Copper is environment-friendly. It has a long history of medicinal use based on its antimicrobial effect dating back to ancient times. The rationale for implementing copper is based on its ability to inhibit microbial growth and to support wound healing.

According to the company, the technology to combine oxidized copper with the polymeric is protected by over 30 patents, globally, and has been developed in over 15 years of intensive research.

The company explains that the wound dressing contains an internal absorbent layer and one or two external non-woven layers, all of which are impregnated with copper particles. Dressings are non-irritant, non-sensitizing.



Read more about: , ,

Wordpress site Developed by Fixing WordPress Problems